Sulfonylureas up cardio events versus metformin

Sulfonylureas up cardio events versus metformin
Use of sulfonylureas for initial treatment of diabetes is associated with increased cardiovascular events and death compared with metformin, according to a study published in the Nov. 6 issue of the Annals of Internal Medicine.

(HealthDay)—Use of sulfonylureas for initial treatment of diabetes is associated with increased cardiovascular events and death compared with metformin, according to a study published in the Nov. 6 issue of the Annals of Internal Medicine.

Christianne L. Roumie, M.D., M.P.H., from the Veterans Affairs Tennessee Valley Healthcare System in Nashville, and colleagues conducted a to compare outcomes for 253,690 veterans who initiated metformin (155,025) or sulfonylurea (98,665) therapy for diabetes. The composite outcome consisted of hospitalization for or stroke, or death, adjusting for baseline demographic and medical characteristics.

The researchers found that crude rates for the composite outcome were 18.2 per 1,000 person-years in sulfonylurea users and 10.4 per 1,000 person-years in metformin users (adjusted incidence rate difference, 2.2 more cardiovascular events with sulfonylureas per 1,000 person-years; adjusted hazard ratio [aHR], 1.21). For both glyburide (aHR, 1.26) and glipizide (aHR, 1.15) results were consistent in subgroup analyses and in -matched cohort and sensitivity analyses.

"These observations support the use of metformin for first-line diabetes therapy and strengthen the evidence about the cardiovascular advantages of metformin compared with sulfonylureas," the authors write.

More information: Abstract
Full Text
Editorial

add to favorites email to friend print save as pdf

Related Stories

Popular diabetes meds put to the test

Nov 06, 2012

(HealthDay)—Patients with diabetes who were treated with the popular oral medication metformin face a lower risk of heart attack, stroke or death than those taking sulfonylureas, another common option, ...

Recommended for you

Drug research and development more efficient than expected

19 hours ago

Drug R&D costs have increased substantially in recent decades, while the number of new drugs has remained fairly constant, leading to concerns about the sustainability of drug R&D and question about the factors that could ...

Use new meningitis vaccines only for outbreaks

Feb 26, 2015

(AP)—A U.S. panel on Thursday recommended that two new meningitis vaccines only be used for rare outbreaks, resisting tearful pleas to give it routinely to teens and college students.

New antibiotic avycaz approved

Feb 26, 2015

(HealthDay)—The combination antibiotic Avycaz (ceftazidime-avibactam) has been approved by the U.S. Food and Drug Administration to treat adults with complicated infections of the intra-abdominal area or urinary tract, ...

Tagging drugs to fight counterfeit medicines

Feb 25, 2015

The U.S. and other countries are enacting rules to clamp down on the sales of fake pharmaceuticals, which pose a public health threat. But figuring out a system to track and authenticate legitimate drugs still faces significant ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.